The German transport and logistics giant finalized the acquisition of CryoPDP, a specialist in cryogenic transport for biopharmaceuticals, on March 31, 2025. This strategic move aims to consolidate its offering in a fast-growing market..

On March 31, 2025, DHL announced the acquisition of CryoPDP, a company specializing in extreme temperature pharmaceutical logistics. This transaction allows the German group to strengthen its capabilities in the transport of biological drugs and other temperature-sensitive products, a sector where the cold chain is critical.

Recognized for its innovative solutions, CryoPDP masters the transport of products at very low temperatures, essential for vaccines, gene therapies, and other highly sensitive pharmaceutical products. Its integration within DHL Supply Chain is expected to create technological and operational synergies to further secure the healthcare supply chain.

"This acquisition consolidates our position in a rapidly expanding market, where regulatory and technical requirements are increasingly strict," DHL emphasizes. The group is thus expanding its offering, now covering all needs: ambient temperature, refrigerated and cryogenic (-80°C to -150°C).

With the rise of innovative therapies (mRNA, cells, and genes), pharmaceutical transport under thermal constraints represents a major challenge. By integrating CryoPDP, DHL is giving itself the means to meet the expectations of laboratories, hospitals, and research centers, while accelerating its development in healthcare logistics.